Given that GIP and GLP-1 are involved in glucose homeostasis, further research on the relationship between hypothalamic AMPK (considered as a regulator of the whole-body energy balance) and GIP/GLP-1 signaling could give insight into possible new therapeutic approaches for the treatment of obesity, diabetes, or neurodegenerative disorders. The gene discussed is GLP1R; the disease is obesity disorder.